Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease.
Mariani A. et al, (2025), Appl Health Econ Health Policy
Association of Daily Steps with Incident Non-Alcoholic Fatty Liver Disease: Evidence from the UK Biobank Cohort.
Fulda ES. et al, (2025), Med Sci Sports Exerc
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Towards an understanding of the ethics of electronic consent in clinical trials.
Sahan K. et al, (2024), Trials, 25
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Effect of Fenofibrate on Progression of Diabetic Retinopathy.
Preiss D. et al, (2024), NEJM evidence, EVIDoa2400179 - EVIDoa2400179
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
Secondary prevention of cardiovascular disease, including cholesterol targets: summary of updated NICE guidance.
Wonderling D. et al, (2024), BMJ, 384
Design, recruitment, and baseline characteristics of the LENS trial
PREISS D. et al, (2024), Diabetic Medicine
Diabetic retinopathy and quality of life: A systematic review and Meta-analysis
Zayed M. et al, (2024), JAMA Ophthalmology
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland
PREISS D. et al, (2023), BMJ Quality and Safety
Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.
Seekircher L. et al, (2023), Eur Heart J Open, 3
SGLT2 inhibitors in CKD and HFpEF: two new large trials and two new meta-analyses.
Mayne KJ. et al, (2023), Br J Cardiol, 30